MediPharm Labs Corp.
LABS.TO
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 13.35% | -12.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.35% | -12.47% | |||
| Cost of Revenue | 31.95% | -20.81% | |||
| Gross Profit | -16.20% | 5.12% | |||
| SG&A Expenses | 58.03% | 6.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 51.25% | -27.56% | |||
| Total Operating Expenses | 43.59% | -11.75% | |||
| Operating Income | -787.94% | -10.63% | |||
| Income Before Tax | -910.31% | 78.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -910.31% | 78.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -910.31% | 78.13% | |||
| EBIT | -787.94% | -10.63% | |||
| EBITDA | -15,019.38% | -114.17% | |||
| EPS Basic | -1,000.00% | 80.00% | |||
| Normalized Basic EPS | -925.00% | -100.00% | |||
| EPS Diluted | -1,000.00% | 80.00% | |||
| Normalized Diluted EPS | -925.00% | -100.00% | |||
| Average Basic Shares Outstanding | 0.05% | 0.80% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||